That is certainly the benefit of us having multiple drugs in the pipeline which further decreases risk. I appreciate the efforts of management and fully support the decision making process with the resources we currently have. As the platforms continue to mature, many doors and avenues of exploration will develop. Patients and shareholders will have lots of upside.
News 
Market Data 
Discover 
AI
